Treatment of dyslipidemia room for improvement?

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 20, Issue 11, 2000, Pages 2333-2335

  Crouse III, John R ^a   Furberg, Curt D ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEZAFIBRATE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN;

ATHEROGENESIS; CARDIOVASCULAR RISK; DISEASE MARKER; DYSLIPIDEMIA; EDITORIAL; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL;

EID: 0033763668     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.20.11.2333     Document Type: Editorial

References (24)

1. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
2. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia
3. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
4. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)
5. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the Multiple Risk Factor Intervention Trial
6. Hypertriglyceridemia, insulin resistance, and the metabolic syndrome
7. Epidemiology of hypertriglyceridemia and cardiovascular disease
8. Counterpoint: To (measure apo) B or not to (measure apo) B: A critique of modern medical decision-making
9. Cholesterol efflux regulatory protein, Tangier disease and familial high density lipoprotein deficiency
10. The role of the high-density lipoprotein receptor SR-B1 in cholesterol metabolism
11. Metabolism of high density lipoprotein subfractions
12. Long-term cholesterol-lowering effects of 4 fat-restricted diets in hypercholesterolemic and combined hyperlipidemic men
13. A-I Milano apoprotein: Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family
14. Cholesteryl ester transfer protein and atherosclerosis
15. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
16. Relation of baseline lipids and lipid changes with gemfibrozil to cardiovascular endpoints in the VA-High Density Lipoprotein Intervention Trial (VA-HIT)
17. Fasting and postprandial remnant-like particles (RLP) as predictors of cardiovascular events in the VA-HDL Intervention Trial (VA-HIT)
18. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: The Bezafibrate Infarction Prevention (BIP) Study
19. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels
20. On-treatment apolipoproteins as predictors for recurrent cardiovascular events in patients with coronary artery disease treated to target levels
21. Effects of high doses of simvastatin and atorvastatin on high-density-lipoprotein cholesterol and apolipoprotein A-1
22. A large 36-week study of the HDL-C raising effects and safety of simvastatin vs atorvastatin
23. Prevalence of dyslipidemic phenotypes in ischemic heart disease (pro-spective results from the Quebec Cardiovascular Study)
24. Nontraditional risk factors for coronary heart disease incidence among persons with diabetes: The Atherosclerosis Risk in Communities (ARIC) study